GLP-1 Medications May Lower Dementia Risk, Research Shows

GLP-1 Medications May Lower Dementia Risk, Research Shows

Although glucagon-like peptide-1 (GLP-1) receptor agonists are primarily intended for managing type 2 diabetes (T2D) and obesity, research continues to uncover additional benefits. The latest exploration suggests that GLP-1 medications may help lower dementia risk.

GLP-1ra may reduce risk of fourteen obesity-related cancers for people with diabetes

A large observational study of more than 170,000 patients with diabetes and obesity in the US has found that glucagon-like peptide-1 (GLP-1) receptor agonists may modestly reduce the risk of fourteen obesity-related cancers, especially colorectal cancer, when compared to dipeptidyl peptidase-4 (DDP-4) inhibitors. The research was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, in Chicago.“Although obesity is no…